Biosergen AB receives approximately SEK 44.9 million through warrants of series TO3
Biosergen AB (”Biosergen” or the "Company") announces today the outcome of the exercise of warrants of series TO3, which were issued in connection with a rights issue in the Company during the first quarter 2024. In total, 91,701,328 warrants of series TO3 were exercised, corresponding to 100.0 percent of the total number of outstanding warrants of series TO3, for subscription of 91,701,328 shares at an exercise price of SEK 0.49 per share. Biosergen will receive approximately SEK 44.9 million before issuing costs through the exercise of the warrants of series TO3. Upon the exercise period